Results of the Phase II MoonStone study of obexelimab in relapsing multiple sclerosis скачать в хорошем качестве

Results of the Phase II MoonStone study of obexelimab in relapsing multiple sclerosis

Amit Bar-Or, MD, FRCPC, University of Pennsylvania, Philadelphia, PA, discusses the results of the MoonStone study (NCT06564311), a 12-week Phase II trial of obexelimab in relapsing multiple sclerosis. Dr Bar-Or reports near-complete suppression of new brain lesions on MRI and no surprising adverse events, supporting a Phase III trial program. This interview is part of our coverage of the 11th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.